Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
AssigneeViking Therapeutics, Inc.
InventorsBrian Lian, Geoffrey E. Barker, Maureen Barnes, Brahmachary Enugurthi, Jake Gonzalez
Life of this patent
Estimating the term…
Abstract
Disclosed herein are formulations of small molecule GIP/GLP-1 dual receptor agonists and uses thereof.
Claims82
A pharmaceutical composition, comprising:
- one or more non-aqueous solvent or a solubility enhancer, comprising less than 20% by weight of the pharmaceutical composition;
- and
- a compound having the structure of formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- Aib is 2-aminoisobutyric acid;
- each instance of J1, J2, and J3 is independently an amino acid selected from Aib, a naturally occurring amino acid, and an unnatural amino acid;
- each instance of J4, J5, J6, J7, J8, J9, J10, and J11 is independently a naturally occurring amino acid or an unnatural amino acid;
- each of n1, n2, n3, n4, n5, n6, n7, and n8 is independently 0 or 1, provided that the sum n1+n2+n3+n4+n5+n6+n7+n8 is 4;
- R1 is selected from the group consisting of —C(═O)(OZ1), —P(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-2 heteroatoms selected from N, O and S, the heteroaryl optionally substituted with 1-2 R7;
- R2 is selected from the group consisting of —C(═O)(OZ2), —P(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-2 heteroatoms selected from N, O and S, the heteroaryl optionally substituted with 1-2 R7;
- each R7 is independently selected from the group consisting of halogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, OR5, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl and 5-10 membered heterocyclyl;
- X and Y each are independently selected from the group consisting of —OR4, NR5R6, C1-6 alkyl and haloC1-6 alkyl;
- each R4 is independently selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C6-10 aryl and C7-11 arylalkyl;
- each R5 is independently hydrogen or C1-6 alkyl;
- each R6 is independently hydrogen or C1-6 alkyl;
- and
- Z1 and Z2 each are independently selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl;
- and
- wherein the compound is not
(canceled)
5-6. (canceled)
(canceled)
(canceled)
12-13. (canceled)
(canceled)
(canceled)
20-23. (canceled)
26-27. (canceled)
31-32. (canceled)
(canceled)
A pharmaceutical composition, comprising:
- one or more non-aqueous solvent or a solubility enhancer, comprising less than 20% by weight of the pharmaceutical composition;
- and a compound having the structure of formula II:
- or a pharmaceutically acceptable salt thereof, wherein:
- “*” indicates a chiral carbon with “S” configuration or “R” configuration;
- R1 is selected from the group consisting of —C(═O)(OZ1), —P(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-2 heteroatoms selected from N, O and S optionally substituted with 1-2 R7;
- R2 is selected from the group consisting of —C(═O)(OZ2), —P(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-2 heteroatoms selected from N, O and S optionally substituted with 1-2 R7;
- each R7 is independently selected from the group consisting of halogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, OR5, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl and 5-10 membered heterocyclyl;
- X and Y each are independently selected from the group consisting of —OR4, NR5R6, C1-6 alkyl and haloC1-6 alkyl;
- each R4 is independently selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C6-10 aryl and C6-10 arylalkyl;
- each R5 is independently hydrogen or C1-6 alkyl;
- each R6 is independently hydrogen or C1-6 alkyl;
- and
- Z1 and Z2 each are independently selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl,
- wherein when Z1 and Z2 are both present, at least one of Z1 and Z2 is not hydrogen.
41-42. (canceled)
(canceled)
47-48. (canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising:
- one or more non-aqueous solvent or a solubility enhancer, comprising less than 20% by weight of the pharmaceutical composition;
- and a compound having the structure selected from the group consisting of:
- and pharmaceutically acceptable salts thereof.
56-57. (canceled)
(canceled)
62-64. (canceled)
(canceled)
(canceled)
72-73. (canceled)
(canceled)
A pharmaceutical composition, comprising:
- lactose;
- and
- a therapeutically effective amount of a compound having the structure of formula II, or a pharmaceutically acceptable salt thereof:
- wherein:
- “*” indicates a chiral carbon with “S” configuration or “R” configuration;
- R1 is selected from the group consisting of —C(═O)(OZ1), —P(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-2 heteroatoms selected from N, O and S optionally substituted with 1-2 R7;
- R2 is selected from the group consisting of —C(═O)(OZ2), —P(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-2 heteroatoms selected from N, O and S optionally substituted with 1-2 R7;
- each R7 is independently selected from the group consisting of halogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, OR5, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl and 5-10 membered heterocyclyl;
- X and Y each are independently selected from the group consisting of —OR4, NR5R6, C1-6 alkyl and haloC1-6 alkyl;
- each R4 is independently selected from the group consisting of hydrogen, C1-6 alkyl,
- haloC1-6 alkyl, C6-10 aryl and C6-10 arylalkyl;
- each R5 is independently hydrogen or C1-6 alkyl;
- each R6 is independently hydrogen or C1-6 alkyl;
- and
- Z1 and Z2 each are independently selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl,
- wherein when Z1 and Z2 are both present, at least one of Z1 and Z2 is not hydrogen.
81-82. (canceled)
(canceled)
86-90. (canceled)
92-93. (canceled)
95-105. (canceled)
107-111. (canceled)
(canceled)
Dependencies are inferred from the claim text.